Craig M. McDonald
About
Craig M. McDonald is a scholar working on Molecular Biology, Psychiatry and Mental health and Biomedical Engineering.
According to data from OpenAlex, Craig M. McDonald has authored 270 papers receiving a total of 11.5k indexed citations (citations by other indexed papers that have themselves been cited), including 157 papers in Molecular Biology, 43 papers in Psychiatry and Mental health and 42 papers in Biomedical Engineering. Recurrent topics in Craig M. McDonald's work include Muscle Physiology and Disorders (152 papers), Cerebral Palsy and Movement Disorders (40 papers) and Neurogenetic and Muscular Disorders Research (35 papers). Craig M. McDonald is often cited by papers focused on Muscle Physiology and Disorders (152 papers), Cerebral Palsy and Movement Disorders (40 papers) and Neurogenetic and Muscular Disorders Research (35 papers). Craig M. McDonald collaborates with scholars based in United States, United Kingdom and Italy. Craig M. McDonald's co-authors include Richard T. Abresch, Paula R. Clemens, David D. Kilmer, William M. Fowler, Richard S. Finkel, Erik Henricson, David J. Birnkrant, Kathi Kinnett, Frederic Shapiro and Ajay Kaul and has published in prestigious journals such as The Lancet, Nature Genetics and SHILAP Revista de lepidopterología.
In The Last Decade
Craig M. McDonald
264 papers receiving 11.1k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Craig M. McDonald United States | 51 | 7.1k | 2.1k | 1.8k | 1.7k | 1.6k | 270 | 11.5k | ||
| Eugenio Mercuri Italy | 75 | 11.0k 1.6× | 5.9k 2.8× | 1.4k 0.7× | 2.4k 1.4× | 1.9k 1.2× | 608 | 20.7k | ||
| Richard S. Finkel United States | 49 | 6.6k 0.9× | 5.4k 2.6× | 1.2k 0.6× | 1.1k 0.6× | 952 0.6× | 232 | 10.9k | ||
| Baziel G.M. van Engelen Netherlands | 70 | 7.3k 1.0× | 1.9k 0.9× | 1.7k 0.9× | 2.1k 1.2× | 3.6k 2.2× | 537 | 18.2k | ||
| Richard T. Abresch United States | 40 | 2.8k 0.4× | 986 0.5× | 955 0.5× | 573 0.3× | 886 0.5× | 98 | 5.1k | ||
| David J. Birnkrant United States | 22 | 3.8k 0.5× | 1.3k 0.6× | 955 0.5× | 1.0k 0.6× | 412 0.3× | 61 | 5.4k | ||
| Laura E. Case United States | 28 | 3.4k 0.5× | 1.1k 0.5× | 721 0.4× | 834 0.5× | 384 0.2× | 86 | 6.0k | ||
| Susan T. Iannaccone United States | 45 | 4.0k 0.6× | 2.9k 1.4× | 451 0.2× | 1.3k 0.7× | 555 0.3× | 159 | 6.9k | ||
| Krista Vandenborne United States | 48 | 2.3k 0.3× | 324 0.2× | 1.5k 0.8× | 793 0.5× | 559 0.3× | 158 | 6.1k | ||
| Jean‐Yves Hogrel France | 43 | 1.6k 0.2× | 416 0.2× | 1.3k 0.7× | 371 0.2× | 875 0.5× | 185 | 5.2k | ||
| Giuseppe Vita Italy | 37 | 2.5k 0.4× | 590 0.3× | 353 0.2× | 815 0.5× | 1.1k 0.7× | 245 | 5.5k |
Countries citing papers authored by Craig M. McDonald
Since
Specialization
Citations
This map shows the geographic impact of Craig M. McDonald's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Craig M. McDonald with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Craig M. McDonald more than expected).
Fields of papers citing papers by Craig M. McDonald
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Craig M. McDonald. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Craig M. McDonald. The network helps show where Craig M. McDonald may publish in the future.
Co-authorship network of co-authors of Craig M. McDonald
This figure shows the co-authorship network connecting the top 25 collaborators of Craig M. McDonald. A scholar is included among the top collaborators of Craig M. McDonald based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Craig M. McDonald. Craig M. McDonald is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Desguerre, Isabelle, Edward Tuttle, Francesco Muntoni, et al.. (2025). Association between exon-skipping therapy with eteplirsen and cardiac outcomes in Duchenne muscular dystrophy. Journal of Neuromuscular Diseases. 13(2). 179–189.
2.
Muntoni, Francesco, James Signorovitch, Gautam Sajeev, et al.. (2024). Meaningful changes in motor function in Duchenne muscular dystrophy (DMD): A multi-center study. PLoS ONE. 19(7). e0304984–e0304984.
3.
Liu, Xin, Chen‐Nee Chuah, Erica Goude, et al.. (2024). Gait Event Detection and Travel Distance Using Waist-Worn Accelerometers across a Range of Speeds: Automated Approach. Sensors. 24(4). 1155–1155.
4.
McDermott, Michael P., Keith R. Abrams, Anna Mayhew, et al.. (2024). Factors Associated With Early Motor Function Trajectories in DMD After Glucocorticoid Initiation. Neurology. 102(10). e209206–e209206.
5.
Done, Nicolae, Edward Tuttle, Basil T. Darras, et al.. (2024). Survival among patients receiving eteplirsen for up to 8 years for the treatment of Duchenne muscular dystrophy and contextualization with natural history controls. Muscle & Nerve. 70(1). 60–70.
6.
Liu, Xin, Erica Goude, Jiahui Hou, et al.. (2024). Gait Characterization in Duchenne Muscular Dystrophy (DMD) Using a Single-Sensor Accelerometer: Classical Machine Learning and Deep Learning Approaches. Sensors. 24(4). 1123–1123.
7.
Jhawar, Sanjay, et al.. (2023). Sleep Disordered Breathing in Children with Neuromuscular Disease. Children. 10(10). 1675–1675.
8.
Rodino‐Klapac, Louise R., et al.. (2023). Assessing the value of delandistrogene moxeparvovec (SRP-9001) gene therapy in patients with Duchenne muscular dystrophy in the United States. SHILAP Revista de lepidopterología. 11(1). 2216518–2216518.
9.
Zaidman, Craig M., Crystal M. Proud, Craig M. McDonald, et al.. (2023). Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged ≥4 to <8 Years) with Duchenne Muscular Dystrophy: 1‐Year Interim Results from Study SRP ‐9001‐103 (ENDEAVOR ). Annals of Neurology. 94(5). 955–968.
10.
Muntoni, Francesco, James Signorovitch, Gautam Sajeev, et al.. (2022). Real-world and natural history data for drug evaluation in Duchenne muscular dystrophy: suitability of the North Star Ambulatory Assessment for comparisons with external controls. Neuromuscular Disorders. 32(4). 271–283.
11.
Servais, Laurent, et al.. (2021). First Regulatory Qualification of a Novel Digital Endpoint in Duchenne Muscular Dystrophy: A Multi-Stakeholder Perspective on the Impact for Patients and for Drug Development in Neuromuscular Diseases. SHILAP Revista de lepidopterología. 5(2). 183–190.
12.
Goemans, Nathalie, James Signorovitch, Gautam Sajeev, et al.. (2019). PRO126 A COMPOSITE PROGNOSTIC SCORE FOR TIME TO LOSS OF WALKING ABILITY IN DUCHENNE MUSCULAR DYSTROPHY (DMD). Value in Health. 22. S864–S864.
13.
Finder, Jonathan D., Oscar H. Mayer, Daniel W. Sheehan, et al.. (2017). Pulmonary Endpoints in Duchenne Muscular Dystrophy. A Workshop Summary. American Journal of Respiratory and Critical Care Medicine. 196(4). 512–519.
14.
Buyse, Gunnar, Thomas Voït, Ulrike Schara, et al.. (2016). Treatment effect of idebenone on inspiratory function in patients with Duchenne muscular dystrophy. Pediatric Pulmonology. 52(4). 508–515.
15.
McDonald, Craig M., K. Bushby, M. Tulinius, et al.. (2016). Ataluren: An Overview of Clinical Trial Results in Nonsense Mutation Duchenne Muscular Dystrophy (P3.162). Neurology. 86(16_supplement).
16.
Bello, Luca, Heather Gordish‐Dressman, Avital Cnaan, et al.. (2015). Genetic modifiers of ambulation in the CINRG duchenne natural history study.. Annals of Neurology.
17.
Bello, Luca, Heather Gordish‐Dressman, Lauren P. Morgenroth, et al.. (2015). Prednisone/prednisolone and deflazacort differ in long term outcomes on ambulation and side effects in the CINRG Duchenne Natural History Study (S50.001). Neurology. 84(14_supplement).
18.
Henricson, Erik, Richard T. Abresch, Avital Cnaan, et al.. (2013). The cooperative international neuromuscular research group Duchenne natural history study: Glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures. Muscle & Nerve. 48(1). 55–67.
19.
McDonald, Craig M., Erik Henricson, Richard T. Abresch, et al.. (2013). The cooperative international neuromuscular research group duchenne natural history study—a longitudinal investigation in the era of glucocorticoid therapy: Design of protocol and the methods used. Muscle & Nerve. 48(1). 32–54.
20.
McDonald, Craig M.. (2002). Physical Activity, Health Impairments, and Disability in Neuromuscular Disease. American Journal of Physical Medicine & Rehabilitation. 81(Supplement). S108–S120.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Eugenio Mercuri Breakdown of academic impact, for papers by Richard S. Finkel Breakdown of academic impact, for papers by Baziel G.M. van Engelen Breakdown of academic impact, for papers by Richard T. Abresch Breakdown of academic impact, for papers by David J. Birnkrant Breakdown of academic impact, for papers by Laura E. Case Breakdown of academic impact, for papers by Susan T. Iannaccone Breakdown of academic impact, for papers by Krista Vandenborne Breakdown of academic impact, for papers by Jean‐Yves Hogrel Breakdown of academic impact, for papers by Giuseppe Vita